Table 1.
Main characteristics and corresponding outcomes of included studies.
| First Author [ref] | Journal | Year | N | Enrol-lment period | Ischemic CMP (%) | Mean follow-up (months) | Age (mean) | Males (%) | LVEF (%) | Type of CRT (pts) | Total deaths | NYHA (% of pts) | mean GFR (ml/kg/1.73 m2) | Parameter (GFR in ml/kg/ 1.73 m2, Cre in mg/ml) | Point esti-mate type | Point estimate (all cause mortality) | 95% CI |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Daly DD[13] | PACE | 2016 | 415 | 2002–2011 | 60.7 | 51.6 | 67.3 | 72.2 | 25.4 | CRT-D (415) | 163 | III/IV: 86.1 | n/a | GFR increment 10-units | HR | 0.94 | 0.87–1.02 |
| Gronda E[14] | Cardiology Journal | 2015 | 375 | 1999–2009 | 48.8 | med: 43 | 66.6 | 80.8 | 28 | CRT-D (277) | 93 | III (mean) | 59.9 | GFR increment 10-units | HR | 0.88 | 0.78–0.98 |
| Eisen A[25] | J Cardiovasc Electrophysiol | 2014 | 453 | 2010–2012 | 69.8 | 12 | 66.2 | 86.5 | <30%: 78.8 | CRT-D (453) | 24 | II-IV: 96 | n/a | GFR< 30 | HR | 0.9 | 0.1–7.5 |
| Bogdan S[15] | J Cardiovasc Electrophysiol, | 2014 | 179 | 2007–2010 | 69 | 48 | 68 | 85 | 24.2 | CRT-P (26)/ CRT-D (153) | 73 | III-IV: 90 | 57.17 | GFR< 60/ increment 1-unit | HR | 2.03/0.97 | 1.14–3.61/ 0.96–0.99 |
| Hoke U[20] | Circ Cardiovasc Qual Outcomes | 2014 | 208 | 2000–2010 | 69 | med: 38.6 | 78 | 79 | 27 | CRT-D/ CRT-P | 84 | III (mean) | 51 | GFR increment 1-unit | HR | 0.975 | 0.959–0.995 |
| Khatib M[23] | European Journal of heart failure | 2014 | 608 | 2000–2011 | 42 | 36 | 66.9 | 77 | 24.8 | CRT-D (404) | 174 | II: 23, III: 67, IV: 10 | 63.5 | GFR< 60 | HR | 1.61 | 1.14–2.30 |
| Hoke U[16] | Diabetes Care | 2013 | 710 | n/a | 57 | 38 | 66 | 75.5 | 25 | CRT | 255 | III (mean) | 69 | GFR increment 1-unit | HR | 0.977 | 0.969–0.985 |
| Morani G[24] | Europace | 2013 | 374 | 2004–2007 | 56 | med: 55 | 69 | 80 | 27 | CRT-P (108)/ CRT-D (266) | 117 | II: 24, III: 62, IV: 14 | 58 | GFR< 60 | HR | 1.45 | 0.91–2.32 |
| Kreuz J[26] | Europace | 2012 | 239 | 2001–2010 | 58.2 | med: 43 | 66.7 | 80.3 | 26 | CRT-D (239) | 59 | II: 27.6, III: 72.4 | n/a | Cre increment 0.2-units | HR | 1.98 | 1.7–3 |
| Verbrugge FH[19] | J Cardiac Fail | 2012 | 172 | 2008–2011 | 48 | 18 | 71 | 68 | 29 | CRT-P (98)/ CRT-D (74) | 21 | II: 31, III: 59, IV: 9 | n/a | GFR< 60 | HR | 3.11 | 1.10–8.81 |
| Van Bommel RJ[17] | JACC | 2011 | 490 | 1999–2007 | 59.8 | 26 | 65.5 | 80 | 24 | n/a | 106 | III (mean) | 69.4 | GFR increment 1-unit | HR | 0.97 | 0.96–0.98 |
| Lin G[18] | European Heart Journal | 2011 | 482 | 1999–2005 | 61.6 | 36.45 | 68.4 | 79.7 | 22.3 | CRT-D (385) | 215 | n/a | 51 median | GFR< 60 | HR | 1.61 | 1.16–2.28 |
| Adelstein EC[22] | Pace | 2010 | 787 | 1999–2007 | 56 | 34 | 67 | 73 | 22 | CRT-D (787) | 230 | IV: 6 | 60 | GFR increment 10-units | Corrected HR for survival improvement | 1.21 | 1.13–1.30 |
| Van Bommel RJ[21] | European Heart Journal | 2010 | 716 | n/a | 59 | 25 | 67 | 79.1 | 25 | CRT-D (660)/ CRT-P (56) | 141 | II: 20. III: 72, IV: 8 | 65 | GFR decrement 10-units | HR | 1.18 | 1.09–1.27 |
| Bai R[28] | J Cardiovasc Electrophysiol | 2008 | 542 | 1999–2005 | 66.6 | 27.1 | 66.4 | 77.1 | 19.9 | CRT-D (395)/ CRT-P (147) | 130 | III: 80.6, IV: 19.4 | n/a | Cre> 1.4 | OR | 4.885 | 1.607–14.850 |
| Shalaby A[27] | Pace | 2008 | 330 | 2003–2005 | 63.6 | 19.7 | 67.3 | 81.8 | 22.4 | CRT-D (330) | 66 | III (mean) | n/a | Cre 1.4–3/Cre increment 0.1-unit | HR | 1.89/ 1.11 | 1.06–3.39/ 1.04–1.17 |
List of abbreviations: N: number of patients, CMP: Cardiomyopathy, CRT: Cardiac Resynchronization Therapy, CRT-D: Cardiac Resynchronization Therapy-Defibrillator, CRT-P: Cardiac Resynchronization Therapy-Pacemaker, NYHA: New York Heart Association, GFR: Glomerular Filtration Rate, Cre: Serum Creatinine levels, HR: Hazard Ratio, OR: Odds Ratio